Back

AstraZeneca’s Etcamah fails late-stage breast cancer trial goal, shares fall 3%

Verifying
  • AstraZeneca said Etcamah failed its late-stage breast cancer trial’s main goal.
  • 3% was the decline in AstraZeneca’s U.S.-listed aftermarket shares.
  • FDA granted Etcamah accelerated approval last week for combination use.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.